METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to reverse liver damage in MASH patients
Disease control Recruiting nowThis study is testing whether an experimental drug called IBI362 can help people with MASH, a serious form of fatty liver disease that causes inflammation and scarring. About 165 adults with confirmed MASH will receive either a low dose, high dose, or a placebo (inactive substanc…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Silencing genes to fight liver scarring: new trial targets serious fatty liver disease
Disease control Recruiting nowThis study is testing an experimental drug designed to 'silence' a specific gene involved in a serious form of fatty liver disease called MASH. The goal is to see if the drug can reduce liver inflammation and scarring (fibrosis) in adults with MASH who have certain genetic risk f…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New shot aims to heal scarred livers in major trial
Disease control Recruiting nowThis study is testing an investigational injection called UBT251 to see if it can improve liver health in adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious form of fatty liver disease that causes inflammation and scarring. About 156 participants will …
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Major 7-Year trial tests weekly shot to halt scarring in fatty liver disease
Disease control Recruiting nowThis study is testing whether a weekly injection called survodutide can improve liver health in adults with MASH, a serious fatty liver disease that causes scarring. About 1,800 participants will be randomly assigned to receive either the real medicine or a placebo (dummy shot) f…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
First human test for promising fatty liver drug begins
Disease control Recruiting nowThis early-stage study is testing whether a new drug called miricorilant can reduce fat buildup in the liver of people with MASH, a serious form of fatty liver disease. Eight participants will take the drug daily for six weeks while researchers measure changes in liver fat produc…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Patients share their stories: what It's really like to live with and manage fatty liver disease
Knowledge-focused Recruiting nowThis study aims to understand the experiences of patients with a serious form of fatty liver disease (MASH) who are enrolled in a specialized care program. Researchers will interview 25 patients twice—once before they start the program and once after—to learn about their expectat…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC